Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study

Leukemia & Lymphoma
Emilio IannittoMassimo Federico

Abstract

Rituximab® provides high response rates and effective disease palliation in patients with splenic marginal zone lymphoma (SMZL). We conducted a phase II trial in patients with SMZL who were either untreated or were splenectomized but had shown disease progression within 1 year after splenectomy. Treatment consisted of six courses of Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone (R-COMP). Fifty-one patients were eligible for the analysis. The overall response rate was 84%. The 6-year progression-free survival and overall survival were 54% and 72%, respectively. Toxicity was substantial (grade≥3 neutropenia: 26%; grade≥3 infections: 8%). Of the 15 deaths, two occurred on treatment (one sepsis and one pneumonia). Six deaths were due to lymphoma progression, four to secondary neoplasia, one to sepsis, one to pneumonia and one to splenectomy complications. R-COMP should be restricted to patients with bulky disease associated with symptoms or to patients with possible histological transformation.

References

Mar 1, 1989·Controlled Clinical Trials·R Simon
Nov 2, 2001·The American Journal of Surgical Pathology·F I CamachoM A Piris
Jul 27, 2002·Clinical Lymphoma·Catherine ThieblemontBertrand Coiffier
Nov 26, 2002·Blood·Vito FrancoEmilio Iannitto
Feb 8, 2003·The Lancet Oncology·Catherine ThieblemontBertrand Coiffier
Mar 5, 2003·British Journal of Haematology·Nilima Parry-JonesDaniel Catovsky
Aug 24, 2004·Cancer Chemotherapy and Pharmacology·Klaus MrossChristine E Swenson
Dec 2, 2004·Blood Reviews·David OscierStephen Johnson
Jan 13, 2006·European Journal of Haematology·Emilio IannittoVincenzo Abbadessa
Feb 24, 2006·Blood·Luca ArcainiUNKNOWN Integruppo Italiano Linfomi
Jun 24, 2008·Leukemia & Lymphoma·Giuseppe VisaniAlessandro Isidori
Mar 31, 2010·Seminars in Hematology·Michael Bennett, Geraldine P Schechter
Dec 2, 2010·Blood·Emilio Iannitto, Claudio Tripodo
May 29, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G CervettiM Petrini
Oct 31, 2013·Expert Review of Hematology·Estella Matutes

❮ Previous
Next ❯

Citations

Apr 15, 2016·Investigational New Drugs·Yaghoub SafdariSafar Farajnia
Nov 9, 2018·British Journal of Haematology·Emilio IannittoCatherine Thieblemont
Mar 19, 2016·Blood·Luca ArcainiMarco Paulli
Aug 1, 2020·The Cancer Journal·Francesco BertoniEmanuele Zucca
Dec 5, 2020·Hematology·Alessandro Broccoli, Pier Luigi Zinzani

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.